Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer.

Tarhini AA, Belani CP, Luketich JD, Argiris A, Ramalingam SS, Gooding W, Pennathur A, Petro D, Kane K, Liggitt D, Championsmith T, Zhang X, Epperly MW, Greenberger JS.

Hum Gene Ther. 2011 Mar;22(3):336-42. doi: 10.1089/hum.2010.078. Epub 2011 Feb 2.

2.

A phase I study of concurrent chemotherapy and thoracic radiotherapy with oral epigallocatechin-3-gallate protection in patients with locally advanced stage III non-small-cell lung cancer.

Zhao H, Zhu W, Xie P, Li H, Zhang X, Sun X, Yu J, Xing L.

Radiother Oncol. 2014 Jan;110(1):132-6. doi: 10.1016/j.radonc.2013.10.014. Epub 2014 Jan 17.

PMID:
24444526
3.

Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.

Langer CJ, Movsas B, Hudes R, Schol J, Keenan E, Kilpatrick D, Yeung C, Curran W.

Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-89-S12-95.

PMID:
9331129
4.

A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).

Choy H, Devore RF 3rd, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, Shyr Y, Johnson DH.

Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):931-7.

PMID:
10863062
5.
6.

Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial.

Socinski MA, Rosenman JG, Schell MJ, Halle J, Russo S, Rivera MP, Clark J, Limentani S, Fraser R, Mitchell W, Detterbeck FC.

Cancer. 2000 Aug 1;89(3):534-42.

PMID:
10931452
7.

High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.

Rosenman JG, Halle JS, Socinski MA, Deschesne K, Moore DT, Johnson H, Fraser R, Morris DE.

Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):348-56.

PMID:
12243807
8.

Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.

Takayama K, Inoue K, Tokunaga S, Matsumoto T, Oshima T, Kawasaki M, Imanaga T, Kuba M, Takeshita M, Harada T, Shioyama Y, Nakanishi Y.

Cancer Chemother Pharmacol. 2013 Dec;72(6):1353-9. doi: 10.1007/s00280-013-2335-2. Epub 2013 Oct 29.

PMID:
24166107
9.

Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial.

Socinski MA, Rosenman JG, Halle J, Schell MJ, Lin Y, Russo S, Rivera MP, Clark J, Limentani S, Fraser R, Mitchell W, Detterbeck FC.

Cancer. 2001 Sep 1;92(5):1213-23.

PMID:
11571735
10.

Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer.

Bepler G, Dilling TJ, Wagner H, Hazelton T, Williams C, Chen DT, Greenberg H, Walsh F, Simon G, Tanvetyanon T, Chiappori A, Haura E, Stevens C.

J Thorac Oncol. 2011 Mar;6(3):553-8. doi: 10.1097/JTO.0b013e31820b8d88.

12.

Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer.

Solomon B, Ball DL, Richardson G, Smith JG, Millward M, MacManus M, Michael M, Wirth A, O'Kane C, Muceniekas L, Ryan G, Rischin D.

Lung Cancer. 2003 Sep;41(3):353-61.

PMID:
12928126
13.

Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.

Marks LB, Garst J, Socinski MA, Sibley G, Blackstock AW, Herndon JE, Zhou S, Shafman T, Tisch A, Clough R, Yu X, Turrisi A, Anscher M, Crawford J, Rosenman J; Carolina Conformal Therapy Consortium.

J Clin Oncol. 2004 Nov 1;22(21):4329-40.

PMID:
15514374
14.

Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.

Pallarés C, Capdevila J, Paredes A, Farré N, Ciria JP, Membrive I, Basterrechea L, Gomez-Segura G, Barnadas A.

Lung Cancer. 2007 Nov;58(2):238-45. Epub 2007 Jul 20.

PMID:
17658655
15.

Phase I study of concurrent real-time tumor-tracking thoracic radiation therapy with paclitaxel and carboplatin in locally advanced non-small cell lung cancer.

Sakakibara-Konishi J, Oizumi S, Kinoshita I, Shinagawa N, Kikuchi J, Kato M, Inoue T, Katoh N, Onimaru R, Shirato H, Dosaka-Akita H, Nishimura M.

Lung Cancer. 2011 Nov;74(2):248-52. doi: 10.1016/j.lungcan.2011.02.009. Epub 2011 Mar 12.

PMID:
21397973
16.

Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer.

Tell R, Sederholm C, Klintenberg C, Franksson L, Brandén E, Hillerdal G, Lönn U, Lindén CJ, Ewers SB, Lamberg K, Mrazek E, Lödén B, Sjögren A, Linné T, Friesland S, Sirzén F.

Anticancer Res. 2008 Sep-Oct;28(5B):2851-7.

17.

[Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].

Mito A, Yamasaki M, Matsuura K, Kajihara T, Nitta T, Awaya H, Arita K, Kashiwado K, Ohashi N.

Gan To Kagaku Ryoho. 2009 Oct;36(10):1653-6. Japanese.

PMID:
19838022
18.
19.

Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.

Rao GG, Rogers P, Drake RD, Nguyen P, Coleman RL.

Gynecol Oncol. 2005 Jan;96(1):168-72.

PMID:
15589596

Supplemental Content

Support Center